214eP Exploratory biomarkers evaluation to enhance characterization and explore treatment response prediction in metastatic ovarian cancer patients undergoing therapy with EVT801, a highly selective VEGFR-3 inhibitor. - Fons, P.; Gomez-Roca, C.A.; Cassier, P.; Delord, J-P.; Rochaix, P.; Korakis, I.; Leonardi, G.C.; Hanvic, B.; Tsoutzidis, N.; Davenne, L.; Mandron, M.; Corsi, A.; et al. (Annals of Oncology, 2025)